The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.
September 5th 2020
The FDA has granted pralsetinib a priority review for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancer.
August 26th 2020
Robert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.
August 24th 2020
Nabil F. Saba, MD, FACP, discusses scheduling challenges with cisplatin in head and neck cancer.
August 20th 2020
Kevin Harrington, BSc, MBBS, PhD, MRCP, FRCP, FRCR, discusses the randomized phase 3 KEYNOTE-048 trial in recurrent/metastatic head and neck squamous cell carcinoma.
August 20th 2020
Tipifarnib demonstrated encouraging antitumor activity in patients with recurrent and metastatic head and neck cancer with high HRAS-mutant variant allele frequency, surpassing historical competitors in the second- or later-line settings.
August 19th 2020
Nabil F. Saba, MD, FACP, discusses emerging sequencing strategies in head and neck cancer.
August 13th 2020
Debio 1143 in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy was found to induce a statistically and clinically significant improvement in overall survival compared with CRT alone in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
July 2nd 2020
A new drug application has been submitted to the FDA for pralsetinib (BLU-667) for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancers.
June 22nd 2020
In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.
June 15th 2020
The FDA has approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus types 16, 18, 31, 33, 45, 52, and 58.
May 9th 2020
The FDA has approved selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.
April 30th 2020
Hoping to minimize the off-target effects associated with radiation in patients with oropharyngeal cancer, investigators are testing the hypothesis that intensitymodulated proton therapy can deliver doses as effectively as the current standard of care with less damage to surrounding tissue.
April 30th 2020
Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.
April 28th 2020
Robert L. Ferris, MD, PhD, director of University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Hillman Professor of Oncology, associate vice chancellor for cancer research, professor of otolaryngology, immunology, and radiation oncology, co-director, Tumor Microenvironment Center, UPMC Hillman Cancer Center, discusses a clinical trial testing ADU-S100/MIW815 plus pembrolizumab (Keytruda) in patients with head and neck cancer.
March 31st 2020
Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.
March 13th 2020
The phase III JAVELIN Head and Neck 100 trial has been terminated after an interim analysis showed that the addition of avelumab to standard-of-care chemoradiotherapy was unlikely to lead to a statistically significant improvement in progression-free survival in patients with untreated locally advanced squamous cell carcinoma of the head and neck.
February 27th 2020
The FDA has granted a breakthrough therapy designation to Debio 1143, an inhibitor of apoptosis protein antagonist, for the treatment of patients with previously untreated, unresectable, locally advanced squamous cell carcinoma of the head and neck in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy
February 21st 2020
If clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.
January 29th 2020
The FDA has granted a priority review designation to a new drug application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.
January 16th 2020
The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.